The field is searching for a combination of clinical features and biomarkers that will identify the disease in people with mild cognitive impairment.
In carriers of a PD-causing mutation, PET scans showed serotonin transporter loss before motor symptoms set in.
Fully automated immunoassay could offer cost-effective screening for AD.
A meta-analysis of 47 studies suggests CSF NfL is particularly elevated in a select few, suggesting it could help in differential diagnosis.
In healthy, older adults specific EEG patterns correlated with plaque and tangle burdens.
Using different techniques, contestants vied for the best way to tell which ADNI participants would develop clinical, cognitive, or imaging signs of Alzheimer’s disease.
Serial amyloid and tau scans in cognitively healthy people indicate that the speed at which a person’s tau accumulates best predicts his or her future cognitive decline.
In a research study, one-fifth of healthy people who learned they were at high risk for AD said they might consider physician-assisted death as a future option.
In ADNI, blood marker exposes ongoing neurodegeneration across disease stages.
Scientists know that the retina changes in people with preclinical AD; alas, there is neither consensus nor convergence in the field of retinal imaging. An upcoming initiative aims to determine which measures are most robust.
Scientists are probing saliva and skin secretions for telltale signs of Parkinson’s disease. Their prize? A diagnostic test at the pre-motor stage.
Diagnostics Accelerator to fund projects that develop dementia biomarkers from patient data.
The method purportedly distinguishes patients from controls with more than 90 percent sensitivity and specificity.
A majority of amyloid PET scans led physicians to change how they managed a patient’s disease. The effect on later outcomes is yet to be come.
Among 20 focus areas, 47 research recommendations cover the gamut from basic science to health disparities.